Absorbed dose to man from the Se-75 labeled conjugated bile salt SeHCAT: concise communication.
The absorbed radiation dose that would result from the oral or intravenous administration of SeHCAT (23-[75Se]selena-25-homotaurocholate) has been calculated using the MIRD tables and formulas and data from measurements of whole-body distribution and from long-term whole-body counting in rats, mice, and man. When SeHCAT is administered to normal subjects, the gallbladder is the critical organ, receiving 12 mrad (oral dose) or 22 mrad (i.v.) per microcurie. The whole-body dose is 1 mrad/microCi, whatever the route of administration. In severe hepatic failure the liver might receive 200 mrad/microCi. The activity likely to be used in routine clinical practice is 10 microCi. Where a whole-body counter is used, an activity of 1 microCi has proved adequate. Even at an administered activity of 25 microCi, the absorbed dose is small compared with established techniques of investigating the gastrointestinal tract.
D000284:Administration, Oral; D000818:Animals; D001822:Body Burden; D002779:Cholestasis / Q000378:metabolism; D004735:Energy Transfer; D005704:Gallbladder / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D051379:Mice; D011829:Radiation Dosage; D011868:Radioisotopes; D051381:Rats; D012643:Selenium; D013656:Taurocholic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution; D014915:Whole-Body Counting
D011868:Radioisotopes; D013656:Taurocholic Acid; C033638:23-seleno-25-homotaurocholic acid; D012643:Selenium